Catalytic Cleavage of Disulfide Bonds in Small Molecules and Linkers of Antibody-Drug Conjugates

被引:32
|
作者
Zhang, Donglu [1 ]
Fourie-O'Donohue, Aimee [2 ]
Dragovich, Peter S. [3 ]
Pillow, Thomas H. [3 ]
Sadowsky, Jack D. [4 ]
Kozak, Katherine R. [2 ]
Cass, Robert T. [1 ]
Liu, Liling [1 ]
Deng, Yuzhong [1 ]
Liu, Yichin [2 ]
Hop, Cornelis E. C. A. [1 ]
Khojasteh, S. Cyrus [1 ]
机构
[1] Genentech Inc, Drug Metab & Pharmacokinet, 1 DNA Way MS 412a, San Francisco, CA 94080 USA
[2] Genentech Inc, Biochem & Cellular Pharmacol, San Francisco, CA 94080 USA
[3] Genentech Inc, Discovery Chem, San Francisco, CA 94080 USA
[4] Genentech Inc, Prot Chem, San Francisco, CA 94080 USA
关键词
SITE-SPECIFIC CONJUGATION; ANTICANCER PRODRUGS; THIOREDOXIN; CYSTEINE; GLUTATHIONE; DELIVERY;
D O I
10.1124/dmd.118.086132
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In cells, catalytic disulfide cleavage is an essential mechanism in protein folding and synthesis. However, detailed enzymatic catalytic mechanism relating cleavage of disulfide bonds in xenobiotics is not well understood. This study reports an enzymatic mechanism of cleavage of disulfide bonds in xenobiotic small molecules and antibody conjugate (ADC) linkers. The chemically stable disulfide bonds in substituted disulfide-containing pyrrolobenzodiazepine (PBD, pyrrolo[2,1-c][1,4]benzodiazepine) monomer prodrugs in presence of glutathione or cysteine were found to be unstable in incubations in whole blood of humans and rats. It was shown the enzymes involved were thioredoxin (TRX) and glutaredoxin (GRX). For a diverse set of drug-linker conjugates, we determined that TRX in the presence of TRX-reductase and NADPH generated the cleaved products that are consistent with catalytic disulfide cleavage and linker immolation. GRX was less rigorously studied; in the set of compounds studied, its role in the catalytic cleavage was also confirmed. Collectively, these in vitro experiments demonstrate that TRX as well as GRX can catalyze the cleavage of disulfide bonds in both small molecules and linkers of ADCs.
引用
收藏
页码:1156 / 1163
页数:8
相关论文
共 50 条
  • [41] Resistance to Antibody-Drug Conjugates
    Garcia-Alonso, Sara
    Ocana, Alberto
    Pandiella, Atanasio
    CANCER RESEARCH, 2018, 78 (09) : 2159 - 2165
  • [42] Antibody-Drug Conjugates (ADCs)
    Laird, Trevor
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2014, 18 (09) : 1073 - 1073
  • [43] Exo-Cleavable Linkers: Enhanced Stability and Therapeutic Efficacy in Antibody-Drug Conjugates
    Watanabe, Tomohiro
    Arashida, Naoko
    Fujii, Tomohiro
    Shikida, Natsuki
    Ito, Kenichiro
    Shimbo, Kazutaka
    Seki, Takuya
    Iwai, Yusuke
    Hirama, Ryusuke
    Hatada, Noriko
    Nakayama, Akira
    Okuzumi, Tatsuya
    Matsuda, Yutaka
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (20) : 18124 - 18138
  • [44] Antibody-drug conjugates with uncleavable linkers for the treatment of non-hodgkin lymphoma.
    Polson, Andrew G.
    Lark, Suzarma C.
    Du, Changchun
    Eaton, Dan
    Elkins, Kristi
    Fuji, Rtina N.
    Go, Mary Ann
    Gray, Alane
    Januario, Tom
    Koeppen, Hartmut
    Lau, Jeffery
    Leach, Will
    McDorman, Elena
    McKeever, Kathleen
    Prabhu, Saileta
    Scales, Suzie J.
    Slaga, Dionysos
    Spencer, Susan
    Williams, Marna
    Xie, David
    Yu, Shang-Fan
    Zheng, Bing
    Ebens, Allen
    BLOOD, 2007, 110 (11) : 162A - 162A
  • [45] Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates
    Dal Corso, Alberto
    Cazzamalli, Samuele
    Gebleux, Remy
    Mattarella, Martin
    Neria, Dario
    BIOCONJUGATE CHEMISTRY, 2017, 28 (07) : 1826 - 1833
  • [46] Control Strategy for Small Molecule Impurities in Antibody-Drug Conjugates
    Gong, Hai H.
    Ihle, Nathan
    Jones, Michael T.
    Kelly, Kathleen
    Kott, Laila
    Raglione, Thomas
    Whitlock, Scott
    Zhang, Qunying
    Zheng, Jie
    AAPS PHARMSCITECH, 2018, 19 (03): : 971 - 977
  • [47] Control Strategy for Small Molecule Impurities in Antibody-Drug Conjugates
    Hai H. Gong
    Nathan Ihle
    Michael T. Jones
    Kathleen Kelly
    Laila Kott
    Thomas Raglione
    Scott Whitlock
    Qunying Zhang
    Jie Zheng
    AAPS PharmSciTech, 2018, 19 : 971 - 977
  • [48] Design, Synthesis, and invitro Evaluation of Multivalent Drug Linkers for High-Drug-Load Antibody-Drug Conjugates
    Chen, Bo
    Gianolio, Diego A.
    Stefano, James E.
    Manning, Charlene M.
    Gregory, Richard C.
    Busch, Michelle M.
    Brondyk, William H.
    Miller, Robert J.
    Dhal, Pradeep K.
    CHEMMEDCHEM, 2018, 13 (08) : 790 - 794
  • [49] Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
    Dugal-Tessier, Julien
    Thirumalairajan, Srinath
    Jain, Nareshkumar
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (04) : 1 - 17
  • [50] Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody-Drug Conjugates for Cancer Therapy
    Johan, Audrey Nathania
    Li, Yi
    PHARMACEUTICALS, 2022, 15 (06)